Humulin M3 (30/70) (Insulin Human)

Humulin M3 (30/70) is prescribed to help control blood glucose levels in adults and children with diabetes.

• For both type 1 and type 2 diabetes mellitus when a mixed insulin regimen is appropriate.
• As the basal (long‑acting) component of a basal‑bolus insulin therapy plan.
• In patients who require a predictable overnight and fasting glucose control.
• When combined with rapid‑acting insulin analogues to cover mealtime carbohydrate intake.
• As an adjunct to oral antidiabetic drugs in type 2 diabetes when additional glucose lowering is needed.

• Insulin human binds to the insulin receptor on cell membranes, triggering autophosphorylation of the receptor’s β‑subunit. This activates the intracellular PI3‑K/Akt signaling cascade, which promotes translocation of GLUT‑4 transporters to the plasma membrane, increasing glucose uptake in muscle and adipose tissue. Concurrently, hepatic gluconeogenesis and glycogenolysis are suppressed, facilitating storage of glucose as glycogen and lowering blood glucose concentrations in the bloodstream.

The most frequently reported adverse reactions to Humulin M3 (30/70) are related to its glucose‑lowering action and injection site.

Common

• Hypoglycemia, presenting as sweating, tremor, hunger, or confusion.
• Redness, swelling, or itching at the injection site.
• Transient weight gain due to increased glucose storage.
• Lipodystrophy, such as localized lipoatrophy or lipohypertrophy.
• Mild peripheral edema.

Serious

• Severe hypoglycemia with loss of consciousness or seizures.
• Immediate hypersensitivity reactions, including urticaria or angioedema.
• Anaphylactic shock, a life‑threatening allergic response.
• Development of insulin antibodies that may alter insulin action.
• Significant electrolyte disturbances such as hypokalemia.

Before initiating therapy with Humulin M3 (30/70), several safety considerations should be reviewed to minimize risk.

• Verify blood glucose levels and adjust dose to avoid hypoglycemia.
• Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced.
• Monitor pregnant or breastfeeding women closely; insulin requirements often change during these periods.
• Assess for a history of allergic reactions to human insulin or excipients.
• Educate patients on proper injection technique and rotation of sites to prevent lipodystrophy.
• Consider dose adjustments during periods of illness, surgery, or changes in physical activity.
• Review concomitant medications that may mask hypoglycemia symptoms.

Humulin M3 (30/70) can interact with other medicines, affecting blood glucose control or insulin action.

Avoid

• Concurrent use of other rapid‑acting insulin analogues without dose adjustment, which may cause severe hypoglycemia.
• Beta‑blockers that blunt hypoglycemia warning signs.

Use with caution

• Oral antidiabetic agents such as sulfonylureas or meglitinides, which increase hypoglycemia risk.
• Corticosteroids, which raise blood glucose and may require higher insulin doses.
• Diuretics, especially thiazides, that can affect potassium levels and insulin sensitivity.
• ACE inhibitors or ARBs, which may potentiate insulin’s glucose‑lowering effect.
• Alcohol, which can cause delayed hypoglycemia after insulin administration.